bioMérieux

🗓 Founded 1963👥 12,091 employees💰 Last funded Apr 1995
Biotechnology Research🌐 biomerieux.com
Website LinkedIn
Pioneering Diagnostics A world leader in the field of in vitro diagnostics for more than 60 years, bioMérieux is present in 45 countries and serves more than 160 countries with the support of a large network of distributors. In 2020, revenues reached €3.1 billion, with over 90% of sales outside of France. bioMérieux provides diagnostic solutions (systems, reagents, software, services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products. bioMérieux is listed on the Euronext Paris stock market. Symbol: BIM – ISIN Code: FR0013280286 Reuters: BIOX.PA/Bloomberg: BIM.FP
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
1963
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
India
1
Frequently asked questions
Who invested in bioMérieux?
bioMérieux has 1 investors on record on gritt.io.
When did bioMérieux last raise funding?
The most recent investment in bioMérieux recorded on gritt.io was in April 1995.
When was bioMérieux founded?
bioMérieux was founded in 1963.
What industry is bioMérieux in?
bioMérieux operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is bioMérieux based?
bioMérieux is headquartered in Marcy-lÉtoile.